Our lead therapeutic candidate IC14 is an investigational anti-CD14 monoclonal antibody
CD14 regulates pathogenic inflammatory responses to infection and injury and targeting it with biologic drugs has great potential across a variety of disease areas. Our therapeutic focus is on cardiovascular diseases that currently have limited or no approved treatments. Initial clinical date in patients with acute decompensated heart failure show a rapid, deep and durable response to our antibody.
Uniquely, we also have a matching diagnostic that, with a few drops of blood and in just a few minutes, both predicts the patient’s risk of disease progression and tracks the direct effect of dosing with IC14.
A phase 2 clinical study in patients with all-cause acute respiratory distress syndrome (ARDS) is also underway, using the same drug and diagnostic test.
Team
We have united world-leaders in medical research, clinical practice and commercialisation.
Meet the team
R&D
IC14 is a novel monoclonal antibody designed to block CD14 – a master regulator of the body’s immune response.
Learn More
Invest
We are a private company, with a noble investment proposition, welcoming support from philanthropists, private investors and government sources.
Partner with us“The chronic diseases that afflict us as we age are largely the result of inappropriate inflammation, so the ability of IC14 to reset the level of inflammation should be game-changing for these diseases.“
– Scientific Advisor, Prof Ian Frazer
